Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) EBITDA Margin (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed EBITDA Margin for 4 consecutive years, with 124.56% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin fell 7013.0% year-over-year to 124.56%, compared with a TTM value of 15.39% through Sep 2025, up 14656.0%, and an annual FY2024 reading of 66.07%, up 313308.0% over the prior year.
  • EBITDA Margin was 124.56% for Q3 2025 at Atara Biotherapeutics, down from 13.58% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 38.72% in Q1 2025 and bottomed at 8928.63% in Q2 2023.
  • Average EBITDA Margin over 4 years is 1674.38%, with a median of 115.71% recorded in 2022.
  • The sharpest move saw EBITDA Margin tumbled -111632bps in 2023, then soared 886226bps in 2024.
  • Year by year, EBITDA Margin stood at 115.9% in 2022, then tumbled by -963bps to 1232.22% in 2023, then surged by 97bps to 38.8% in 2024, then plummeted by -221bps to 124.56% in 2025.
  • Business Quant data shows EBITDA Margin for ATRA at 124.56% in Q3 2025, 13.58% in Q2 2025, and 38.72% in Q1 2025.